Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors
Summary
, , and to join the Board of Directors Revagenix, Inc. is advancing a focused pipeline of antibiotic programs designed to treat infections caused by multidrug-resistant organismsSAN FRANCISCO, Jan. 5, 2024 /PRNewswire/ -- Revagenix, Inc., a biopharmaceutical company dedicated to the discovery and development of novel antibiotics, today announced the appointment of Cristina Larkin, Bruce Montgomery, MD, and Michael Lamprecht, PhD, to its board of directors in conjunction with closing its Series B funding round from core investors Tenmile and Novo Holdings. Ryan Cirz, PhD, Chief Executive Officer and director, highlighted these developments as important milestones in the growth of the Company that will enable its mission of creating life-changing antibiotics through scientific innovation and strategic leadership. "Antibiotic resistance represents one of the most significant public health crises of our time and is a major unmet medical need for patients with drug-resistant infections," Dr. Cirz said. The Companys board is chaired by Tina Marriott, President and Chief Operating Officer of Recursion.Tenmile managing director Steve Burnell, PhD said Revagenix represented a beacon of hope in the fight against antibiotic resistance. The teamcomposed of seasoned industry experts, and augmented by a world-class network of strategic collaborators, partners, investors, and advisorsleverages extensive experience in anti-infective research, development, and commercialization.